Dabur will report its Q2 numbers on November 3 and the Street is expecting health, hygiene and immunity products to lead domestic revenue growth. However, out of home products like juices and some skincare products may not do well due to the lockdown. Likewise, international business is expected to see subdued growth of 3 to 5 percent.

A CNBC-TV18 poll predicts a 5.50 percent growth for Dabur in topline. EBITDA is likely to come at 8.50 percent and that would mean margins would improve by around 7 basis points and net profits to come in at Rs 441 crore.

To know more, watch the video.

(Edited by : Jerome Anthony)